This article presents an analytical overview of 10 new cardiac solutions driving advancements in cardiovascular care. These companies develop technologies such as AI-driven ultrasound sensors for precise cardiac imaging, non-invasive intracardiac pressure monitoring for continuous patient assessment, and remote cardiac device monitoring systems for improving real-time patient management.
Further, innovative heart failure treatments are emerging, offering targeted therapies for improved patient outcomes. Each company contributes to the evolving landscape of cardiac healthcare, addressing critical needs in diagnostics, monitoring, and treatment. The integration of these technologies highlights the expanding role of cardiac health companies in enhancing patient care and advancing medical practices.
Continue reading to gain up-to-date and data-driven insights on:
Key Takeaways
Drawing insights from the Big Data & AI-powered StartUs Insights Discovery Platform that provides data on over 4.7+ million emerging companies globally, we explore the evolving landscape of the cardiac industry. This sector is marked by key trends and a substantial workforce, shaping its future. 5 days ago, we last updated this report. Notice something that’s not right? Let’s fix it together. Here are some key insights at a glance:
- Current Cardiac Industry Trends: Some of the pivotal trends in the cardiac industry are wearables, AI, telemedicine, 3D printing, and genomics.
- Cardiac Industry Statistics: The sector comprises 38K+ organizations worldwide. Out of these, 3K+ new cardiac solution companies were founded in the last five years, with 2020 as the average founding year. On average, each of these companies employs about 58 people. Moreover, the average funding received by these 6K+ companies per round in the same span is USD 21 million.
- 10 Best Cardiac Solutions to Watch:
- RhythmScience – Remote Cardiac Device Monitoring
- SafeBeat Rx – Cardiac Therapeutics Monitoring
- Levron Cardiovascular – Heart Failure Treatment
- Forcefield Therapeutics – Cardioprotective Proteins
- AccurKardia – ECG Interpretation Software
- Pumpinheart – Preserved Ejection Fraction
- Phlox Therapeutics – Gene-based Cardiac Therapy
- Cauchy Analytics – AI Ultrasound Sensor
- Kardi Ai – Home Cardiac Monitoring
- Acorai – Non-invasive Intracardiac Pressure Sensor
Discover 10 out of 38K+ Emerging Cardiac Solutions
In this section, we spotlight 10 top cardiac solutions companies focusing on cardioprotective proteins, ECG interpretation software, and preserved ejection fraction technologies. These companies integrate advanced biomedical research, software algorithms, and diagnostic techniques to improve patient outcomes and treatment accuracy. Explore further to discover more innovative heart health solutions these companies offer in the evolving field of cardiovascular care.
Note on Signal Strength
One of the unique metrics we feature for each company is Signal Strength, a proprietary data point generated by our Discovery Platform. It gauges the extent to which a company’s influence has permeated the global ecosystem of startups, scaleups, and emerging companies. This proprietary metric serves as a valuable guidepost for understanding a company’s standing in the broader market landscape.
1. RhythmScience
- Founding Year: 2019
- Employee Range: 51-200
- Location: USA
- Signal Strength: Very Strong
- What they do: RhythmScience develops a cloud-based cardiac care software that simplifies follow-up of remote and in-person cardiac devices and data to manage patients with complex chronic conditions. The platform enables bidirectional integration with electronic health records (EHR) for data handling and automated billing. The Rhythm360 platform detects arrhythmia and faults with cardiac devices and alerts doctors in real-time. The system includes features like built-in compliance tools and comprehensive cardiology reports that capture data from implantable and wearable devices. Customizable alerts and multi-modal monitoring prioritize urgent issues, which in turn optimize workflows and reduce staff workload.
2. SafeBeat Rx
- Founding Year: 2020
- Employee Range: 2-10
- Location: USA
- Signal Strength: Very Strong
- What they do: SafeBeat Rx develops an AI-powered platform for cardiac therapeutic monitoring via mobile devices. The SafeBeat platform integrates FDA-cleared cardiac monitoring devices, including mobile ECGs, mobile cardiac telemetry, and implantable monitors to provide clinicians with real-time diagnostic insights and personalized treatment recommendations. The system includes remote therapeutic monitoring (RTM) and event monitoring capabilities to improve remote patient care. The company’s proprietary machine learning algorithms further ensure accurate ECG interpretation and efficient treatment management. The platform simplifies clinician workflows without being buried in alerts and notifications. Cardiologists and their patients benefit from SafeBeat’s data-driven cardiac care solutions to improve treatment accessibility and outcomes.
3. Levron Cardiovascular
- Founding Year: 2021
- Employee Range: 2-10
- Location: Israel
- Signal Strength: Strong
- What they do: Levron Cardiovascular develops a minimally invasive therapeutic device for the New York heart association (NYHA) stage-3 heart failure that targets lung congestion and dyspnea. This device operates as a closed-loop system to shift fluids away from the lungs to reduce cardiac workload and improve respiratory function. The company’s technology prevents cardiac decompensation by adapting treatment in real time based on patient needs. The system also mitigates symptoms while lowering the risk of acute cardiac events. The device provides a continuous, adaptive response to changing physiological conditions, increasing patient stability and quality of life.
4. Forcefield Therapeutics
- Founding Year: 2020
- Employee Range: 2-10
- Location: UK
- Signal Strength: Very Strong
- What they do: Forcefield Therapeutics develops biotherapeutics to preserve heart function after myocardial infarction (MI) by protecting cardiomyocytes. The company’s approach identifies cardioprotective proteins using a drug discovery method that bypasses traditional disease or target-focused biases. The identified proteins maintain cardiac function by preventing cell death and promoting tissue repair. This reduces the progression to heart failure, benefiting patients who experience acute MI. Forcefield’s proprietary proteins are currently under development as therapeutic agents to mitigate the severe impact of heart attacks.
5. AccurKardia
- Founding Year: 2019
- Employee Range: 11-50
- Location: USA
- Signal Strength: Very Strong
- What they do: AccurKardia develops AccurECG, a cloud-based solution for fully automated ECG interpretation. This FDA-cleared, HIPAA-compliant system features proprietary algorithms, ensuring accurate analysis of ECG data from various compatible devices. The platform includes AccurWeb for ECG recording review and AccurAPI for integration with custom applications. AccurECG provides beat-by-beat analysis, supraventricular and ventricular ectopic beat detection, and interpretation of 13 different heart rhythms. The system offers explainable results that avoid the black-box issue and deliver efficient outputs for clinical use. This ECG interpretation solution thus benefits medical device manufacturers, cardiac monitoring companies, and telehealth service providers.
6. Pumpinheart
- Founding Year: 2022
- Employee Range: 2-10
- Location: Ireland
- Signal Strength: Very Strong
- What they do: Pumpinheart develops a device for treating heart failure with preserved ejection fraction (HFpEF). The PReduction device, an ECG-gated implantable diastolic pump, reduces left atrial pressure during diastole and exercise, mitigating symptoms of HFpEF. This device features a transcutaneous energy transfer system (TETS) for power and control, connected via a driveline to sensors and the pump in the left ventricle. It is delivered through a minimally invasive transcatheter procedure that makes it accessible for use in cath labs. Designed for NYHA Stage C and D HFpEF patients, the device reduces hospitalizations and improves quality of life. Pumpinheart benefits healthcare providers by reducing costs and hospitalizations while improving patient outcomes and quality of life.
7. Phlox Therapeutics
- Founding Year: 2022
- Employee Range: 2-10
- Location: Netherlands
- Signal Strength: Very Strong
- What they do: Phlox Therapeutics develops gene therapies for heart diseases, focusing on rare genetic cardiomyopathies. The company’s PHL-001 targets cardiac laminopathies through advanced RNA-based therapeutics that offer precision treatment by simultaneously addressing multiple Lamin mutations. This approach bypasses the need for mutation-specific compounds, benefiting patients with diverse genetic profiles. Phlox Therapeutics’ platform also enables curative solutions for patients receiving palliative care. The company addresses unmet medical needs in the cardiac space, aiding patients suffering from severe and often fatal genetic heart conditions.
8. Cauchy Analytics
- Founding Year: 2022
- Employee Range: 11-50
- Location: Canada
- Signal Strength: Medium Strong
- What they do: Cauchy Analytics develops AI-driven ultrasound sensors for continuous, non-invasive heart monitoring in Intensive Care Units (ICUs). These sensors provide real-time 3D imaging and blood flow measurements to offer instantaneous echocardiographic views and accurate ejection fraction data. The system, which includes compact sensors placed on the patient’s chest, enhances cardiac care by reducing the time between monitoring and diagnosis. The technology prioritizes patient comfort with disposable gel adhesives and allows for continuous monitoring over several days. The solution improves patient outcomes and reduces hospital-associated costs.
9. Kardi Ai
- Founding Year: 2022
- Employee Range: 11-50
- Location: Czechia
- Signal Strength: Very Strong
- What they do: Kardi Ai builds an ECG monitoring platform for continuous heart rhythm analysis. This system integrates the Polar H10 chest belt with a cloud-based application that provides real-time data on heart health. The platform’s AI evaluates ECG recordings to offer immediate results and detailed reports for medical professionals. Kardi Ai facilitates the detection and diagnosis of arrhythmias, including paroxysmal atrial fibrillation. It benefits patients by providing constant access to heart health data and facilitating proactive medical intervention.
10. Acorai
- Founding Year: 2019
- Employee Range: 11-50
- Location: Sweden
- Signal Strength: Very Strong
- What they do: Acorai develops a non-invasive intracardiac pressure monitoring device that facilitates heart failure management. The device uses the patented SAVE Sensor System, which integrates seismic, acoustic, visual, and electrical sensors to capture real-time intracardiac data. This data is processed through proprietary machine learning models, providing precise insights into intracardiac pressure without the need for invasive procedures. The handheld device is user-friendly and easily integrated into clinical practices. The company provides heart failure care that offers a scalable solution to reduce hospital readmissions and improve patient outcomes.
Quick Tip to Find New Cardiac Solutions
Utilizing a SaaS platform like the Discovery Platform for identifying new cardiac solutions provides significant benefits compared to traditional scouting methods:
- Streamlined Efficiency: The Discovery Platform offers advanced tools that streamline the scouting process. It replaces your hours of conventional desk research, saving time and resources in identifying cardiac innovations.
- Access to Real-time Insights: Gain a competitive edge with up-to-date information on the latest trends in the cardiac industry. The platform keeps you informed with near real-time updates on emerging cardiac solutions and news, enabling you to make swift and informed decisions.
- Tailored Exploration: Customize your search to focus on specific niches within the cardiac sector, such as cardioprotective proteins, preserved ejection fraction, or non-invasive intracardiac pressure. The platform’s diverse filtering options allow you to target your scouting efforts precisely, ensuring that you find the most relevant and groundbreaking companies in the field.
Ready to Explore All New Cardiac Solutions?
We’ve explored the dynamic landscape of the cardiac industry, examining the latest trends and spotlighting exceptional companies driving innovation. To dive deeper, download our free Healthcare Report or schedule a demo of the Discovery Platform for a customized exploration of these groundbreaking developments. We seek partnerships with industry experts to deliver actionable insights into startups and tech. Interested? Let us know!
